Table 4.
Combination of immune checkpoint inhibitors.
| STUDY (#=non cited in the text) |
AGENTS | PHASE | SETTING | %MSS | PRIMARY ENDPONT | RESULTS*
*In the experimental arm when applicable |
|---|---|---|---|---|---|---|
|
NCT02870920
(52) |
durvalumab + tremelimumab VS best supportive care | II | Metastatic, pretreated | 99 | OS | 6.6 vs 4.1 months |
|
NCT02720068
(53) |
pembrolizumab + favelizumab | I | Metastatic, third or more | 100 | safety | Manageable, antitumor activity observed |
|
NCT03860272
(54) |
botensilimab ± balstilimab | I/II | Metastatic, pretreated | 100 | ORR, DCR | 24%, 73% |
|
NCT03377361
CheckMate 9N9 |
nivolumab + trametinib ± ipilimumab | I/II | Metastatic, pretreated | 100 | Safety and tolerability | Ongoing |
| NCT03642067# | nivolumab + relatlimab | II | Metastatic or locally advanced | NA | ORR | Ongoing |
NA, not available.